Patents Represented by Attorney, Agent or Law Firm Venable, Baetjer, Howard & Civiletti, LLP
  • Patent number: 5622685
    Abstract: Tumor-active or tumor-diagnostic substances having preferred accumulation in the tumor, which are characterized in that they haveat least two phenolic hydroxyl and/or amino groups,at least one aliphatic amino group, orat least one phenolic hydroxyl and/or amino group andat least one aliphatic amino groupand that these groups are substituted with polyethylene glycol chains whose polymerization degree n is 5 to 250 and whose terminal hydroxyl group is substituted by C.sub.1 -C.sub.12 alkyl ester or ether, each of the substances being substituted by at least two such polyethylene glycol chains.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 22, 1997
    Assignee: Deutches Krebsforchunszentrum Stiftung des Offentlichen Rechts
    Inventors: Hans J. Sinn, Hans-Hermann Schrenk, Wolfgang Maier-Borst, Eckhard Friedrich, Georgi Graschew, Dieter Wohrle, Thomas Klenner
  • Patent number: 5619323
    Abstract: Advanced boresight equipment and methods of using the same to effect a transfer of a two- or three-dimensional frame of reference from an ADL to a device to be boresighted.The equipment includes a stationary inertial sensor that is boresighted with respect to a reference line (such as the aircraft ADL). The stationary inertial sensor includes a first gyroscopic combination for generating a first output indicating a two- or three-dimensional frame of reference based on the ADL, and a docking station. The docking station facilitates alignment of a portable inertial sensor that also has a gyroscopic combination for generating a second output indicating its frame of reference.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: April 8, 1997
    Assignee: AAI Corporation
    Inventors: Stephen B. Hamilton, James J. Jaklitsch, Christopher J. Reed, Charles E. Schulz, Leslie H. Debelius, Jr., Niall B. McNelis, Edward B. Baker
  • Patent number: 5614372
    Abstract: The invention relates to a bioaffinity assay of prostate-specific antigen (PSA) comprising the measurement of either the concentration of total PSA (PSA-T), the concentration of free form of PSA (PSA-F) or the concentration of PSA complexed to alpha-1-antichymotrypsin (PSA-ACT), PSA-T being the sum of PSA-F and PSA-ACT. According to the invention, additionally the concentration of human glandular kallikrein (hGK-1) is measured. The concentrations of PSA-T and hGK-1 can be measured in one single assay or in separate assays. The sum of the concentrations of PSA-T and hGK-1 is used to determine the ratio a) PSA-F/(PSA-T+hGK-1) and/or b) PSA-ACT/(PSA-T+hGK-1). Both of these ratios are shown to have clinical utility for the discrimination of prostate cancer and benign prostatic hyperplasia.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: March 25, 1997
    Inventors: Hans Lilja, .ANG.ke Lundwall, Janita Lovgren
  • Patent number: 5605799
    Abstract: The present invention is directed to somatic mutations of the NF1 gene which are found in human tumors. In addition, the present invention is directed to methods of screening humans to determine those having somatic mutations in the NF1 gene in tumors. Finally, the invention is directed to a method of treating a human having a tumor with a somatic mutation in the NF1 gene by restoring natural regulation of ras proteins.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: February 25, 1997
    Assignee: University of Utah Research Foundation
    Inventors: Raymond L. White, Richard M. Cawthon, Ying Li
  • Patent number: 5599673
    Abstract: The invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that SCN5A and HERG cause long QT syndrome. Molecular variants of the SCN5A and HERG genes contribute to the syndrome. The analysis of these genes will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequences of the SCN5A or HERG genes of an individual to be tested and comparing them with the nucleic acid sequence of the native, nonvariant genes. Alternatively, the amino acid sequences of SCN5A or HERG may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: February 4, 1997
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Mark E. Curran, Qing Wang
  • Patent number: 5593832
    Abstract: This invention relates to a method for identification of samples collected as physical evidence for forensic analysis. The identification is based upon an analysis of DNA length polymorphisms generated by the action of restriction endonucleases.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: January 14, 1997
    Assignee: Lifecodes Corporation
    Inventor: Jeffrey Glassberg
  • Patent number: 5591821
    Abstract: The present invention is directed to .omega.-conotoxin peptides having 24-30 amino acids, six cysteines which form disulfide bonds between the first and fourth, second and fifth, and third and sixth cysteines, respectively, and an internal sequence of Cys-Arg-Lys-Thr-Xaa.sub.1 -Tyr-Xaa.sub.2 -Cys-Cys-Ser-Gly-Ser-Cys (SEQ ID NO:1). The invention is further directed to .omega.-conotoxin peptides of the generic formula Cys-Xaa.sub.1 -Gly-Xaa.sub.2 -Gly-Ala-Xaa.sub.3 -Cys-Arg-Lys-Thr-Xaa.sub.4 -Tyr-Xaa.sub.5 -Cys-Cys-Ser-Gly-Ser-Cys-Xaa.sub.6 -Arg-Gly-Xaa.sub.7 -Cys (SEQ ID NO:2). Preferably, the C-terminus is amidated. These peptides also contain three disulfide bonds. Examples of .omega.-conotoxin peptides within the generic formula are MVIIC having the formula Cys-Cys-Gly-Lys-Gly-Ala-Xaa.sub.1 -Cys-Arg-Lys-Thr-Xaa.sub.2 -Tyr-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Arg-Gly-Lys-Cys (SEQ ID NO:3), wherein Xaa is preferably Pro or Hyp (4-hydroxyproline) and Xaa.sub.
    Type: Grant
    Filed: July 16, 1993
    Date of Patent: January 7, 1997
    Assignee: The University of Utah
    Inventors: Baldomero M. Olivera, David R. Hillyard, Julita S. Imperial, Virginia D. Monje
  • Patent number: 5589198
    Abstract: This invention relates to a composition for use in the treatment or prevention of iodine deficiency diseases or disorders such as fibrocystic dysplasia of the breast, breast cancer, endometriosis, ovarian cysts and premenstrual syndrome. More particularly, this invention relates to a composition for the treatment or prevention of iodine deficiency diseases or disorders, the composition comprising elemental iodine (I.sub.2) which may also be referred to as metallic iodine or iodine metal. The elemental iodine can be used with any pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: December 31, 1996
    Assignees: 943038 Ontario, Inc., Bernard A. Eskin
    Inventors: Bernard A. Eskin, R. Alison Ghent
  • Patent number: 5589340
    Abstract: The invention is directed to A-lineage conotoxin peptides, which are conotoxin peptides that have strong homology in the signal sequence and the 3'-untranslated region of the genes coding for these peptides to the sequences in the .alpha.-conotoxin peptides. The A-lineage conotoxin peptides include the .alpha.-conotoxin peptides, the .alpha.-conotoxin-like peptides and the .kappa.-conotoxin peptides, described further below. The .alpha.-conotoxin-peptides generally share a "core" sequence motif. This core sequence is termed the .alpha. 3/5 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO: 1). The .alpha.-conotoxin-like peptides generally share a core sequence termed the .alpha. 4/7 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO: 2). The .kappa.-conotoxin peptides generally have a core sequence termed the .kappa.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 31, 1996
    Assignee: University of Utah Research Foundation
    Inventors: Baldomero M. Olivera, Lourdes J. Cruz, David R. Hillyard, J. Michael McIntosh, Ameurfino D. Santos
  • Patent number: 5589584
    Abstract: The association of molecular variants of the angiotensinogen gene with human essential hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood presure.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: December 31, 1996
    Assignee: University of Utah Research Foundation
    Inventors: Jean-Marc Lalouel, Xavier Jeunemaitre, Richard P. Lifton, Florent Soubrier, Youri Kotelevtsev, Pierre Corvol
  • Patent number: 5587369
    Abstract: The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA, DHEA derivatives or DHEA congeners to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA, DHEA derivatives or DHEA congeners to a patient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 24, 1996
    Assignee: University of Utah Research Foundation
    Inventors: Raymond A. Daynes, Barbara A. Araneo
  • Patent number: 5583126
    Abstract: The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuries, and thus to prevent or reduce the consequent progressive necrosis of tissue associated with such ischemia. This effect is achieved by administering DHEA or DHEA derivatives to a patient as soon as possible after the injury. The present invention is further directed to methods for preventing or reducing bacterial translocation or adult respiratory distress syndrome in a patient. Similarly, bacterial translocation and adult respiratory distress syndrome are prevented or reduced by administering DHEA or DHEA derivatives to a patient. Suitable derivatives of DHEA include, among others, 16.alpha.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: December 10, 1996
    Assignee: University of Utah Research Foundation
    Inventors: Raymond A. Daynes, Barbara A. Araneo
  • Patent number: 5575597
    Abstract: The present invention relates to a computer aided design and manufacturing system. The system comprises a platform suspended by means of three pairs of supportive legs which are coupled at triangularly spaced-apart locations by means of three universal joints, each of which couples to one end of each of the two legs of a respective pair. The two legs of each pair extend from their respective universal joint in divergent directions to spaced-apart locations in an overhead mounting where each leg is drivingly engaged by a respective gimbal-mounted electric motor arranged to move the leg in its own longitudinal direction. The platform position and orientation can be controlled by appropriate operation of the six leg drive motors.
    Type: Grant
    Filed: October 5, 1993
    Date of Patent: November 19, 1996
    Assignee: Geodetic Technology International Holdings N.V.
    Inventors: Ralph P. S. Bailey, Jerome J. Leary
  • Patent number: 5573394
    Abstract: A low-profile burner assembly (LPBA) with pilot for creating realistic firefighter training fires in a controlled setting. The LPBA generally includes a sealed pipe fitting shell with a fuel inlet for inputting combustible fuel, an air inlet for inputting air to be mixed with the fuel, a spark ignition system coupled to the pipe fitting shell for igniting a pilot flame, and a main burner outlet for outputting a combusting air/fuel mixture to create a firefighting training flame. Fuel is distributed within the pipe fitting by an internal distribution tube for metering pilot and main burner portions, and for proper mixing with air. In addition, a sensor probe assembly is provided for monitoring the LPBA. All internal components are well-protected from the high-pressure spray of extinguishing agents by a transport/deflector assembly.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: November 12, 1996
    Inventor: John C. Pershina
  • Patent number: 5569051
    Abstract: Disclosed is a waterproof connector which is capable of controlling the inserting posture of the terminal members with respect to the connector housing in the earlier stages of terminal insertion. The waterproof connector includes: a plurality of terminal members having inserting posture controlling protrusions; and a connector housing having a plurality of terminal accommodating chambers for accommodating the terminal members. A waterproof plug which has a plurality of sealing insertion holes corresponding to the terminal accommodating chambers is fitted into the rear section of the connector housing, and a waterproof plug retaining cover is mounted on the rear end section of the housing. The waterproof plug retaining cover has terminal insertion holes corresponding to the sealing insertion holes, and the terminal insertion holes have inserting posture controlling recesses allowing passage of the inserting posture controlling protrusions formed on the terminal members.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: October 29, 1996
    Assignee: Yazaki Corporation
    Inventors: Takayoshi Endo, Takashi Takagishi
  • Patent number: 5562910
    Abstract: The invention relates to a vaccine which comprises an antigen and an immune response augmenting agent. The immune response augmenting agent is capable of enhancing T cell lymphokine production. Suitable immune response augmenting agents include, but are not limited to, dehydroepiandrosterone (DHEA) and DHEA-derivatives. Examples of DHEA derivatives include DHEA-sulfate (DHEA-S), 16.alpha.-bromo-DHEA, 7-oxo-DHEA, 16.alpha.-bromo-DHEA-S and 7-oxo-DHEA-S.The invention also relates to a method for enhancing a vaccine-induced humoral immune response which comprises administering a vaccine which comprises an antigen and an immunomodulator. The immunomodulator may be an immune response augmenting agent, a lymphoid organ modifying agent or a mixture of the immune response augmenting agent and lymphoid organ modifying agent. Suitable lymphoid organ modifying agents include, but are not limited to, 1,25-dihydroxy Vitamin D.sub.3, biologically active Vitamin D.sub.
    Type: Grant
    Filed: September 9, 1993
    Date of Patent: October 8, 1996
    Assignee: University of Utah Research Foundation
    Inventors: Raymond A. Daynes, Barbara A. Araneo
  • Patent number: 5557637
    Abstract: A communication system that reduces significantly the processing required to search over unknown time delays and unknown frequency shifts. Convolutional type processing with a unique re-indexing of the desired signal's Fourier transform is provided so as to allow for the design of a communication system that is invariant to time of arrival and frequency shift such as that caused by doppler effects from moving vehicles or moving satellites. The processing required is several orders of magnitude less computationally intensive than conventional approaches to solving this problem. In addition, the inventive convolutional ambiguity multiple access (CAMA) system can be used in conjunction with M-Ary FSK (Frequency Shift Keying) and other coding techniques to decode the various frequency codes efficiently.
    Type: Grant
    Filed: September 24, 1994
    Date of Patent: September 17, 1996
    Inventor: Thomas W. Glynn
  • Patent number: 5552920
    Abstract: An optically-based communication system hosted on an elevated platform (e.g., a satellite a tower, or other platform having a substantial vantage point) that uses multiple spatially diverse transmit and receive beams that are optically cross coupled to fully reuse the spectrum and which will create a fully interactive, high bandwidth, high capacity, fully switched communication system. The elevated platform (i.e., satellite, orbiting or tethered vehicles, airborne platforms, towers, etc.) reuses its assigned bandwidth in each of (N) multiple beams (or sectors). The beams are formed by either RF or optical means. The specific users in each beam are then spatially separated in frequency by use of an optical "Bragg Cell." The separated signals are then duplicated through a half mirror and a full mirror and recombined optically to create outputs that are unique combinations of frequencies from each full set of input beams.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 3, 1996
    Inventor: Thomas W. Glynn
  • Patent number: D376292
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: December 10, 1996
    Assignee: Libbey, Inc.
    Inventor: Steve A. Unger
  • Patent number: D376293
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: December 10, 1996
    Assignee: Libbey, Inc.
    Inventor: Steve A. Unger